223 N Mathilda Ave
Tel: (800) 239-5230
23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named by Glassdoor as one of The Best Places to Work. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021. More information is available at www.23andMe.com.
Stock Symbol: ME
Stock Exchange: NASDAQ
Discover Your DNA Story With 23andMe!
168 articles with 23andMe
A study conducted by 23andMe and published in Nature Genetics identified a genetic risk factor tied to the loss of smell from COVID-19.
23andMe today provided an update on its collaboration with GlaxoSmithKline plc (“GSK”).
Based on the success of a joint immuno-oncology antibody collaboration program targeting CD96, GlaxoSmithKline and 23andMe have extended their 2018 collaboration for an additional year.
23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker
23andMe Holding Co., a leading consumer genetics and research company, received FDA clearance for a genetic health risk report on a hereditary prostate cancer marker.
1/10/2022The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants - Dec 28, 2021
23andMe Holding Co., a leading consumer genetics and research company, announced the results of the completed redemption of all of its outstanding warrants to purchase shares of Class A common stock of 23andMe that were issued under the Warrant Agreement, dated October 1, 2020, by and between 23andMe and Continental Stock Transfer & Trust Company, as warrant agent.
12/21/2021The year kicked off with a bang as multiple companies raced to a public listing.
23andMe raised $592 million in proceeds from the IPO and, as of September 30, had about $700 million. With that cash in hand, it plans to push faster and deeper into drug development.
23andMe Announces the Appointment of Joseph R. Arron, M.D., Ph.D. as Chief Scientific OfficerDr. Arron brings nearly two decades of scientific leadership in biotech drug discovery and development to 23andMe’s Therapeutics team
23andMe Holding Co., a leading consumer genetics and therapeutics company, announced the appointment of Joseph R. Arron, M.D., Ph.D., as the company’s new Chief Scientific Officer.
23andMe Holding Co. announced that it will redeem all of its outstanding warrants to purchase shares of Class A common stock of 23andMe that were issued under the Warrant Agreement, dated October 1, 2020, by and between 23andMe and Continental Stock Transfer & Trust Company, as warrant agent, as part of the units sold in the initial public offering of 23andMe, which was formerly known as VG Acquisition Corp., and that remain outstanding at 5:00 p.m.
This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.
Many mergers took place in 2021. Here’s a look at some of the hottest life sciences SPAC merger announcements so far in 2021. Many mergers took place in 2021,
23andMe Holding Co. today announced the signing of a definitive merger agreement with Lemonaid Health, Inc.
Wanting to find out what is fueling the trend, BioSpace solicited the perspectives of a couple of executives who chose the SPAC route.
23andMe Holding Co., a leading consumer genetics and research company, announced that management will be participating in the Wells Fargo Virtual Healthcare Conference on Friday, September 10, 2021 at 8:20 a.m. Pacific Time / 11:20 a.m. Eastern Time.
23andMe Holding Co., a leading consumer genetics and research company, reported its financial results for the first quarter of its fiscal year 2022, which ended June 30, 2021.
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industr...
23andMe Successfully Closes its Business Combination with VG Acquisition Corp.Combined Company to Trade on Nasdaq Under Ticker “ME” Commencing June 17
23andMe, Inc., a leading consumer genetics and research company, and VG Acquisition Corp., a special purpose acquisition company sponsored by Virgin Group, announced the completion of their previously announced business combination.
Michael J. Fox Foundation and 23andMe Share New Genetic Data from the Largest Cohort in Parkinson's Research
Collaboration with 23andMe enables robust sharing of de-identified genetic data with researchers worldwide through the Fox Insight Data Exploration Network (Fox DEN)